人々が一般的な健康診断に資金を提供し、実施し、受診する理由は何か？ 主な結果 - 一般的な健康診断を受けるかどうかは、一般的な健康診断の存在を知っているか、家族、友人、医療提供者から促されるかなど、いくつかの要因に基づいて決定される。一般的な健康診断や治療が無料でない場合、時間やお金といった資源も重要な役割を果たす。悪い結果を恐れて、一般的な健康診断を避ける人もいる。 - 医療費提供者や医療提供者についての情報が少なかったため、一般的な健康診断への資金提供や実施について、何が彼らの決断の原動力となっているのか、完全には理解できていない。 - 一般的な健康診断を受けるかどうかについては、長所と短所を天秤にかけ、自分の健康状態や状況を考慮しながら、慎重に考えるべきである。 一般的な健康診断とは？ 一般的な健康診断とは、特に裕福な国で、健康だと感じている人に定期的に行われる健康診断のことである。さまざまながんのスクリーニングや、糖尿病や心臓病にかかるリスクの評価などである。これらの検査は、リスクや病気を早期に発見して治療したり、生活習慣を変えたりするのに役立つと考えられている。しかし、リスクがあるかもしれない。たとえば、スクリーニング検査で間違った診断を受け、さらに検査を受けなければならなくなったり、不必要な治療を受けなければならなくなったりする可能性がある。一般的な健康診断には費用が...

Catherine Spencer OBE, who served as the Cochrane Collaboration’s Chief Executive Officer since 2022, has decided to step down from the role.

Catherine has led Cochrane through transformational change, developing a new strategy for a more evidence-informed world and ensuring the organization is well-placed to deliver it. She has helped to cement Cochrane’s reputation as a world-leading source of trustworthy evidence and expand the charity’s reach and impact around the world.

“I have been so fortunate to work with incredibly talented and loyal colleagues, Board Members and community members,” said Catherine. “All have worked hard to ensure that Cochrane has a great future and is a wonderful environment in which to work and grow. I wish all the team well as they focus on the continued success of Cochrane.”

The Governing Board has appointed Dr Karla Soares-Weiser as Acting CEO while they prepare to recruit the next CEO. Cochrane’s Deputy Editor-in-Chief, Toby Lasserson, will serve as Acting Editor-in-Chief.

Dr Susan Phillips, Chair of Cochrane’s Governing Board, said:

“The Governing Board would like to thank Catherine for her valued contribution to Cochrane and Cochrane community. In her time as CEO, she has ensured that the organization has a warm and collaborative culture that fosters innovation and trust.

“We wish to acknowledge the important contribution Catherine has made towards stabilizing Cochrane’s operations, developing the 2024-2027 Organizational Strategy, supporting Cochrane’s transition to a centralized editorial service and implementing the Roadmap to Open Access.

“Consequently, Cochrane is in a strong position, and we anticipate building on these achievements. Our priorities will be to strengthen Cochrane’s evidence synthesis model, including our use of AI tools, and to develop business models and methods which make us more responsive to funders’ needs.”

Preparations to recruit the next CEO will be led by Cochrane’s Governing Board.

Wednesday, March 12, 2025

March 2025 marks the third anniversary of Cochrane’s commitment to Public Involvement in Health and Social Care Research, a pledge launched in 2022. This commitment underscores Cochrane's ongoing efforts  to enhance its practice of public involvement, ensuring that the voices of the users of our evidence are at the heart of health and social care evidence.

Excellent public involvement is an essential part of health and social care research and improves the quality and impact of research. Excellent public involvement is inclusive, values all contributions, ensures people have a meaningful say in what happens, and influences outcomes, as set out in the UK Standards for Public Involvement.

Cochrane is proud to be one of the thirty two organizations in partnership on this important initiative. Together, partners connect during quarterly Learning and Sharing meetings to share best practices and new developments, amplifying excellent public involvement and maximising resources for optimised efforts and impact.

Reflecting on this milestone, April English, Cochrane’s Consumer Engagement Manager, states: “Our commitment to public involvement is key to advancing health and social care research and demonstrating our value for the invaluable contributions of patients and the public, ultimately improving the quality and impact of research.”

“People have the right to be involved in all health and social care research,” Ana Beatriz Pizarro, member of the Consumer Network Executive, reflects. “People’s lived experiences should be a key driver for health and social care research.”

Key Achievements and Initiatives

Over the past three years, Cochrane has taken significant steps to strengthen public involvement, including:

• Cochrane’s Consumer Network: In 2025, three new members joined the Consumer Network Executive, and as of January 2025, over 2,500 members have joined the Consumer Network. Both, strengthening the community of people interested in high-quality health evidence, and in helping to be a part of producing and sharing evidence.
• Reporting Consumer Involvement: Since 2024, all new Cochrane reviews must report on consumer involvement.
• Consumer Representation on Editorial Board: The Editorial Board is responsible for supporting Cochrane’s Editor in Chief and overseeing the production of Cochrane Reviews and other Cochrane Library content. The Editorial Board includes representation from the Consumer Network.
• Consumer Peer Review of Submitted Cochrane Reviews and Protocols: Recent consumer peer reviews include Electronic cigarettes for smoking cessation, Interventions implemented through sporting organisations for promoting healthy behaviour or improving health outcomes, Prevention of self‐harm and suicide in young people up to the age of 25 in education settings, and Water fluoridation for the prevention of dental caries. 
• The Co-Production Methods Group: Launched in October 2023, this group advances research on co-production methods, shares best practices, and supports learning to help systematic review authors engage meaningfully with healthcare consumers.
• Evidence Essentials:  A free, online learning module co-produced by healthcare consumers, researchers, and Cochrane specialists, helping people understand health evidence and make informed health choices. In 2024, module six was launched on critical appraisal of rapid reviews.
• Learning Live Webinars:  A series of free webinars tailored for different audiences, including review authors and the public, providing guidance on engaging with Cochrane evidence and making research more accessible.

Cochrane’s Framework for Public Involvement

Cochrane’s framework for consumer engagement and involvement focuses on five key elements:

1. Engagement: Strengthening communication, evidence dissemination, recruitment, and learning opportunities for consumers.
2. Co-Production: Increasing consumer involvement in evidence production and governance to align research with user needs.
3. Accessibility: Enhancing health literacy and making Cochrane evidence easier to access and understand.
4. Strategic Partnerships: Collaborating with patient groups and other stakeholders to advance engagement, co-production, and advocacy efforts.
5. Evaluation and Reporting: Establishing key engagement and involvement metrics for evaluating and reporting the impact of Cochrane’s engagement and involvement activity. 
   
   
   

How to Get Involved?

There are many ways to play a part in health and social care research  at Cochrane.

Join Cochrane's Consumer Network, a large and growing community of people across the world. We welcome patients, carers and the public who are interested in getting involved in and sharing high-quality health evidence.

Cochrane Engage and Cochrane Crowd are always looking for volunteers to get involved with research.

• Learn more about Cochrane’s commitment to healthcare consumers
• Contact the Cochrane’s Consumer Engagement Manager or Cochrane’s Consumers Network Executive at consumers@cochrane.org 
  

 

Tuesday, March 11, 2025

抗うつ薬は、非特異的な腰痛や脊椎（背骨）に関連した下肢痛がある人に効果があるか？ 主な結果 - セロトニン・ノルエピネフリン再取り込み阻害薬（抗うつ薬の一種）は、プラセボ（非活性錠剤またはダミーの錠剤）と比較すると、腰痛がある人の痛みの強さをわずかに軽減し、機能をわずかに改善すると考えられる。これらの薬を服用することで、好ましくない影響が出る人もいるであろう。 - プラセボと比較すると、三環系抗うつ薬（抗うつ薬の一種）は、腰痛のある人の機能にわずかな改善をもたらすが、痛みの強さにはおそらくほとんど影響を与えない。 - 脊椎に関連した下肢痛に対する抗うつ薬の効果については不明である。 腰痛と脊椎に関連した脚の痛みとは？ 腰痛は、世界中で障害を引き起こす主要な原因となっている。腰痛のほとんどは、脊椎の明確な損傷によって引き起こされるものではないため、「非特異的」と呼ばれる。腰痛がある人の多くは、脚への放散痛も経験している。 腰痛と脊椎に関連した下肢痛を、 抗うつ薬でどのように治療するのか？ 抗うつ薬は、もともとうつ病を治療するために開発された一群の薬である。最も一般的なクラスには、セロトニン・ノルエピネフリン再取り込み阻害薬、選択的セロトニン再取り込み阻害薬、三環系抗うつ薬がある。抗うつ薬は、神経系における痛みの信号を遮断することによって痛みを和らげると考えられている。抗うつ薬を服用...

Title:  Digital Marketing Manager
Specifications: Permanent – Full Time
Salary: £52,000 per annum
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 19 March, 2025

The Digital Marketing Manager is an exciting new role that reflects the strategic importance of digital marketing to Cochrane, an internationally renowned charity providing high-quality health evidence.

You will establish and oversee the organization’s digital marketing function, recruiting and managing a part-time (0.6 FTE) Digital Marketing Officer. Together you will deliver high-quality, targeted digital marketing campaigns that inspire engagement and support from a range of audiences.

This role will oversee both brand marketing for diverse audiences and B2B/B2C marketing aimed primarily at universities and academics. Brand marketing will involve ownership of Cochrane’s social media accounts and oversight of email marketing, working closely with colleagues who manage the CRM (SugarCRM). Commercial marketing will include promoting academic conferences, on-demand training courses, and specialist software (SaaS).

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 19 March, 2025. We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24 March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits

 

Friday, March 7, 2025 Category: Jobs

血管拡張薬（血管を広げる薬）は、不妊症の女性が妊娠するのに役立つか？ 要点 1．血管拡張薬は、ダミーの治療や無治療と比べると、妊娠するのにおそらく役立つが、副作用もあるだろう。また、血管拡張薬は、ダミーの治療や無治療と比べると、あるいはエストロゲン（女性ホルモン）と比べると、妊娠が継続できて出産するまでの可能性にはほとんど影響しないかもしれない。 2．より確かな結論を出すためには、この治療に関する、より大規模でしっかりデザインされた研究が必要である。 背景 不妊治療を受けている女性にとって、胚盤胞（受精卵が数日間分裂して、胎児のもとが作られた状態）が子宮内膜に正常に着床することが重要である。着床率や出生率を高める可能性がある薬はたくさんある。その一つに、血管拡張薬がある。この薬は、血管を拡張して子宮内膜を厚くし、子宮の収縮を防ぐことで、胚盤胞を子宮に着床しやすくすると考えられている。 知りたかったこと 血管拡張薬が生児出生率、妊娠率、子宮内膜の厚さを改善するのに役立つかどうかを調べたかった。また、血管拡張薬が多胎妊娠（双子、三つ子など）、流産、異所性妊娠（受精卵が子宮内膜以外に着床すること）の発生率に影響を及ぼすかどうか、副作用があるかどうかも知りたかった。 実施したこと 年齢を問わず、不妊治療を受けている女性を対象に、血管拡張薬とプラセボ（ダミーの治療）または無治療とを比べた研...

A new Cochrane review has found evidence that music-based therapy may benefit people living with dementia, particularly by improving symptoms of depression. 

Dementia is a collective term for progressive degenerative brain syndromes that affect memory, thinking, behaviour and emotion. Alzheimer’s Disease International reported that there were 55 million people with dementia worldwide in 2019, a figure predicted to increase to 139 million by 2050. While some medicines are available, the therapeutic use of music is considered a relatively simple and inexpensive approach that remains accessible even in the later stages of dementia.  

The research team from several institutions in the Netherlands examined evidence from 30 studies involving 1,720 people. The studies investigated the effects of music-based therapeutic interventions on emotional well-being including quality of life, mood disturbance, behavioural problems, social behaviour, and cognition. Most participants were in care homes, with interventions delivered either individually or in group settings. 

The trials were primarily conducted in high-income countries, including Australia, Taiwan, the US, and various European countries.  Almost all the therapies included active elements (such as playing instruments), often combined with receptive elements (such as listening to live music provided by a therapist).

"This review increases our understanding of the effects of music therapy and strengthens the case for incorporating music in dementia care, particularly in care home settings.

“Music therapy offers benefits beyond those of other group activities, helping to support mood and behaviour in a way that is engaging and accessible, even in later stages of dementia. Care home managers should consider integrating structured musical sessions as part of a person-centred approach to dementia care.”

- Jenny van der Steen, lead author from Leiden University Medical Center and Radboudumc Alzheimer Center.

The findings suggest that music-based therapy probably improves depressive symptoms and may improve overall behavioural problems by the end of treatment. Music therapy is unlikely to significantly impact agitation, aggression, emotional well-being, or cognition but, when compared to other interventions, there is some evidence that it may improve social behaviour and could decrease anxiety. 

Long-term effects, beyond four weeks after treatment, may be smaller but remain uncertain due to the limited number of trials monitoring effects after treatment ends.

The review also highlights the growing recognition of non-pharmacological interventions in dementia care. 

“Music therapy is a drug-free way of helping people feel less sad and less anxious. We hope that the higher quality of recent studies and increasing evidence-base will result in more attention being given to music therapy and other non-pharmacological approaches.

"Looking at the effect sizes, music therapy is a reasonable alternative to pharmacological approaches and is much more person-centred.”

- Annemieke Vink, co-author from ArtEZ University of the Arts who has first-hand experience delivering music therapy to people with dementia.

The review underscores the need for further research into the long-term effects of music-based therapy particularly in community settings. Much of the existing evidence comes from care homes, so expanding studies to community-based environments could provide valuable insights into how music therapy can be integrated into everyday life for people living with dementia.

• Read the Cochrane review and the plain language summary
• Read the press release in Spanish

 

Wednesday, March 5, 2025

Title:  Systematic Reviewer
Specifications: Permanent – Part time (0.6 FTE)
Salary: £45,000 per annum (£27,000 per annum at 0.6 FTE)
Location: (Remote) resident in the UK, Germany or Denmark. 
Directorate: Development and External Relations Directorate
Closing date: 17 March, 2025

As a Systematic Reviewer you will assist with the provision and delivery of commissioned systematic reviews and review tasks for Cochrane Response, Cochrane’s evidence consultancy unit.

Cochrane Response provides a broad range of literature review and evidence synthesis services to international policy makers and guideline developers to support evidence informed healthcare decision making. We work closely with Cochrane networks to increase Cochrane’s capacity to respond to requests for commissioned evidence reviews and tailored evidence services.

This position is aligned with Cochrane’s strategy to secure the long-term sustainability of the organisation by ensuring the success of Cochrane Response as a business unit that produces relevant information to guide healthcare decisions and responds to the needs of our stakeholders.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 17th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on w/c 24th March 2025.
• Read our Recruitment Privacy Statement.
• Read our Candidate pack for more information on the hiring process and staff benefits.

 

Tuesday, March 4, 2025 Category: Jobs

We are delighted to announce a new, joint Methods Group between the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE) focusing on artificial intelligence (AI) and automation in evidence synthesis. 

The rapidly growing evidence base and the increasing complexity of methods makes completing timely, high-quality, and comprehensive evidence synthesis, more and more challenging. Artificial intelligence (AI) and automation promises to help address this, and make it possible to keep up with the demand and expectations of users of evidence synthesis. But to realize this potential, we - as a collective across the whole evidence synthesis ecosystem - need to ensure AI doesn’t compromise on the principles of research integrity in which evidence synthesis was built. Therefore, this Methods Group will help define and support responsible AI use across four of the leading evidence synthesis organizations, including the Cochrane Collaboration, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE).   

As a Methods Group, we aim to: 

• Spearhead methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 
• Define best practice and ensure guidance for accepted methods is up to date. 
• Support the implementation of new or amended methods by acting as an advisor or through involvement in methods implementation in our respective evidence synthesis organizations.  

Spearheading methods research and development and act as a bridge between evidence synthesis organizations and the wider research community. 

We are part of the International Collaboration for Automation in Systematic Reviews (ICASR) and recommend those who want to share and discuss AI methods research, developments and opportunities, do so via the ICASR LinkedIn group, as we will as a Methods Group. 

Across our Methods Group, we are also involved in other key developments in the evidence synthesis ecosystem, including the Evidence Synthesis Infrastructure Collaborative safe and responsible use of AI working group. 

Our aim is for the Methods Group to work across these organizations and developments in the field and facilitate discussion and critical thinking, particularly around standards for accuracy, evaluations and validation, with events, webinars and other activities.  

Defining best practice and ensuring guidance for accepted methods is up to date. 

We are involved the responsible AI use in evidence synthesis recommendations and guidance (RAISE), which offers tailored advice for a diverse range of roles in the evidence synthesis ecosystem. Whether you're an evidence synthesist, methodologist, AI developer, or an organization or publisher involved in evidence synthesis, this guidance is a first step to help clarify your responsibilities and alleviate some of the concerns around AI use. For more information see the RAISE Open Science Framework project page. 

One of our first actions as a Methods Group will be to  provisionally endorse the next version of the RAISE recommendations and guidance for use in Cochrane, the Campbell Collaboration, JBI and the Collaboration for Environmental Evidence (CEE), which  is due to be released soon. 

Supporting the implementation of new or amended methods by acting as an advisor or through involvement in the methods implementation projects.  

The Methods Group has individuals from across four of the major evidence synthesis organizations, and even though implementation of AI and automation is the responsibility of each organization individually, by coming together we can aim to align best practice and share lessons learned on effective approaches. Our implementation will be based on the RAISE recommendations, with more details being shared in the coming months.  

As a first step, we are in the process of defining our position on AI and automation for researchers and authors within our organizations, to ensure they have clarity and are empowered to use them in their evidence synthesis. 

Our implementation will also consider how we can we improve AI literacy across our organizations, including how we can work with methodologists and trainers, so researchers and editors have the skills they need to ensure AI is used responsibly and reported transparently.  

 

Methods Group Convenors: 

• Ella Flemyng (Cochrane, UK)
• Gerald Gartlehner (University for Continuing Education Krems and Cochrane Austria, Austria)
• Zoe Jordan (JBI, Australia)
• Biljana Macura (Stockholm Environmental Institute and the Collaboration for Environmental Evidence, Sweden)
• Joerg Meerpohl (University of Freiburg and Cochrane Germany, Germany)
• Will Moy (Campbell, UK)
• Anna Noel Storr (Cochrane, UK)
• James Thomas (UCL, UK) 

Want to find out more? 

Register for the webinar on ‘Recommendations and guidance on responsible AI in evidence synthesis’ on 3 June 2025, part of the Artificial Intelligence (AI) methods in evidence synthesis series, to find out about why we all need to embrace responsible AI and how this Methods Group will support it. 

Also see our AI Methods Group website, which includes a news and events section. You can also follow each individual organization for more news and information as the Group develops. 

 

 

Friday, February 28, 2025

Title:  Head of Publishing Operations 
Specifications: Permanent – Full Time 
Salary: £63,000 per annum 
Location: (Remote) resident in the UK, Germany or Denmark.  
Directorate: Publishing and Technology Directorate 
Closing date: 14 March, 2025 

We are seeking an experienced and proactive Head of Publishing Operations to lead and manage Cochrane’s publishing systems and processes. In this key role, you will act as liaison between internal teams, external technology suppliers, and our publishing partner, ensuring smooth, efficient and innovative xml-first workflows from submission to publication. You will oversee the performance of our publishing technology, manage vendor relationships, and drive continuous improvements to our production processes. With a strong focus on operational excellence, stakeholder collaboration, and author experience, you will play a pivotal role in ensuring Cochrane’s publishing systems and processes are efficient, reliable, and aligned with our strategic goals. 

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally. 

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate. 

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. 

How to apply 

• For further information on the role and how to apply, please click here. 
• The deadline to receive your application is 14th March, 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible. 
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Interviews will be held on w/c 24th March, 2025.
• Read our Recruitment Privacy Statement
• Read our Candidate pack for more information on the hiring process and staff benefits 

Friday, February 28, 2025 Category: Jobs

産後出血を予防、発見、治療するための、世界保健機関（WHO）の勧告を実現させるにはどんな対策が優れているか？ 主なメッセージ 複数の対策を組み合わせると、世界保健機関（WHO）の産後出血（PPH）を予防するための勧告により従えるようになる可能性があるが、集中治療室（ICU）への入院、追加の手術が必要になる数、または妊産婦の死亡数には恐らく差はない。複数の対策を組み合わせることが、出血量や輸血の有無に影響するかどうかはわからない。 一つだけの対策では、WHOのPPH予防のための勧告が守られるかどうか、出血量、または輸血の有無に影響するかどうかはわからない。一つだけの対策では、妊産婦の死亡数には差がなく、ICUへの入院が増えるかもしれない。一方、追加の手術を必要とする数が減る可能性がある。 研究の件数が少なく、解析した研究の間で収集されたデータに差があるなどの限界があって、有効な対策について結論を出すことができなかった。しかし、同一の対策が、異なる研究で程度の違いこそあれ成功を収めており、今後この領域での研究を行う必要性が非常に高い。 産後出血（PPH）とは何か？ 産後出血（PPH）とは、通常、出産後24時間以内に500mlを超える出血があること、と定義される。 PPHはどのようにして予防、診断、治療されているか？ WHOのガイドラインは、PPHを予防するために、出産直後にオキシトシ...

Title:  Head of Finance
Specifications: Permanent – Full Time
Salary: £63,000 per annum
Location: (Remote) based in the UK, Germany or Denmark.
Closing date: 7 March, 2025

As an experienced and qualified Accountant, you will lead and manage Cochrane’s finance functions; developing and implementing strategies, policies and systems to ensure that they are provided in an effective and efficient manner to support the strategic aims and operational activities of the organisation. You will also contribute to Cochrane’s financial sustainability through inputs to fundraising, product & business development and robust financial management.

Reporting to the Director of Finance & Corporate Services, you will lead our small, friendly and dedicated Finance Team, responsible for the effective management and control of the financial function of a medium sized dynamic Charity. This is a pivotal role leading the financial outcomes, which will directly support senior leadership and top-level decision making and closely partner an array of key non-finance colleagues across the Charity.

Joining our team means becoming part of a mission to enhance global health through reliable, evidence-based practices. You'll collaborate with dedicated professionals and partners worldwide to ensure health decisions are informed by the best available data. Our core values — collaboration, relevance, integrity, and quality — guide all our actions. By joining us, you'll contribute to making a significant impact on health outcomes globally.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace.

So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 7 March 2025.  We reserve the right to close this vacancy early if we receive sufficient applications for the role. Therefore, if you are interested, please submit your application as early as possible.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Interviews will be held on 20 and 21 March 2025.
• Read our Recruitment Privacy Statement
• Read our Candidate pack for more information on the hiring process and staff benefits

Monday, February 24, 2025 Category: Jobs

うつ病を対象とした母乳育児支援介入は、産後のうつ病発症を予防できるか？ 主な結果 - 心理社会的な母乳育児支援介入は、支援を受けてから1～3か月後の母親の産後うつ病の一部を予防し、支援を受けてから7～12か月後の母乳育児期間を延長する可能性がある。その他のメンタルヘルスや母乳育児の結果に対する影響については、非常に不確かなエビデンスしかない。 - 母乳育児支援以外の介入（特にマインドフルネス）が産後うつ病やその他のメンタルヘルス、母乳育児の結果に与える影響に関するエビデンスは、非常に不確かである。 - 介入に直接関係する有害事象は記載されていなかったが、ほとんどの研究で有害事象が測定されているかどうかはわからなかった。 - 今後の母乳育児支援介入研究は、バイアスのリスクを減らすために慎重に実施されるべきであり、母親の精神的健康状態の差を検出するのに十分な規模でなければならない。 産後うつ病とは何か？ 産後うつ病は、出産後に起こる精神疾患で、抑うつ気分や、活動に対する喜びや興味の喪失が長期間続くことが特徴である。母親、赤ちゃん、そして家族全体に深刻な影響を及ぼしかねない病気である。 知りたかったこと うつ病を対象とした母乳育児支援介入が、産後うつ病の予防や産後うつ病の症状の軽減において、標準的な産後ケアよりも優れているかどうかを調べたいと考えた。また、母乳育児支援介入に有害な副作用...

We are pleased to announce that earlier this week, Cochrane’s status as a non-State actor (NSA) in official relations with the World Health Organization (WHO) was renewed at the 156th session of the WHO Executive Board meeting in Geneva.

The Executive Board is composed of 34 technically qualified representatives from different Member States, elected for three-year terms. Every year, the Executive Board meets at WHO headquarters to discuss global health priorities for the year ahead and sets the agenda for the World Health Assembly.

The renewal of our official relations status is underpinned by a new joint plan of work for the next three years, which focuses on providing WHO with evidence syntheses that will help inform guidelines, the essential medicines list, methodological assistance and training, supporting activities that facilitate the use of evidence in policymaking at country, regional and global levels, alongside other technical assistance.

This official relation status also enables us to join and make statements at key WHO meetings as a non-voting participant. This includes the World Health Assembly (WHA), WHO’s decision-making body, which is attended by representatives of all Member States, and is a key forum to advocate for evidence-informed health policies and resolutions.

Cochrane was represented at this year’s Executive Board meeting by Governing Board member, Emma Persad; CEO, Catherine Spencer; and Advocacy and Partnerships Officer, Mariam Salman.

The session began with an opening statement by Dr Tedros Adhanom Ghebreyesus, WHO Director-General. He highlighted the key achievements of the past 12 months and welcomed the adoption of the Fourteenth General Programme Of Work (GPW14), which Cochrane were invited to consult on through our NSA in official relations status.

He mentioned that maternal health is the theme for World Health Day this year and that although we have made progress on maternal and child mortality, we still have a long way to go to reach the Sustainable Development Goals (SDGs).

The Director-General also applauded Science Division, stating that its normative and standard-setting function is helping ensure that Member States are given the highest quality, evidence-based advice as fast as possible.

As part of the discussions, Cochrane submitted a statement to the Executive Board for consideration. Our statement supported the adoption of a draft resolution on strengthening national capacities in evidence-based decision making, as well as advocating for the production of high-quality evidence.  The full statement can be read below:

“Honorable Chair, Esteemed Delegates,

For over 30 years, the Cochrane Collaboration has been at the forefront of improving global health and life expectancy. We produce high-quality and trusted synthesized evidence to inform health decision making.

In a dramatically changing world with overlapping global health challenges, this is more vital now than ever.

We therefore urge Member States to adopt the Resolution titled “Strengthening national capacities in evidence-based decision making for the uptake and impact of norms and standards”

We also acknowledge that in order to ensure the production of high-quality evidence, the relevant WHO departments need core, recurrent funding for this essential function to continue its impact on a country-level.

We are pleased to see the alignment between WHO’s priorities and the Cochrane Collaboration’s Scientific Strategy, and express our sincerest gratitude and support in our ongoing engagement.”

• For more information on the work that Cochrane does with WHO and this year’s Executive Board meeting, please email msalman@cochrane.org.
• Find out more about the 156th session of the Executive Board.

Thursday, February 13, 2025

不妊治療を受けると卵子がたくさんできてしまう女性にとって、最善の治療とは何か？ 主なメッセージ 多嚢胞性卵巣症候群（卵巣で成熟卵子がうまく作られない状態）の女性が不妊治療を受ける場合、体外成熟（未熟な卵子を、受精に十分な成熟度まで体外で育てること）が体外受精（卵子を体外で精子と受精させる治療法）よりも生児出産や妊娠を増やすのに優れているかどうかはわかっていない。 体外成熟は、体外受精に比べて流産を増加させる。一方、多嚢胞性卵巣症候群の女性における卵巣過剰刺激症候群（卵巣が卵子を過剰に産生する痛みを伴う状態）を減少させる。 早産（妊娠37週未満での出産）と胎内での赤ちゃんの発育については、体外成熟と体外受精ではほとんど差がないが、より多くの研究が必要である。 論点 なかなか妊娠しない女性は、妊娠する可能性を高めるための治療を必要とする場合がある。これには、女性が卵子の成熟を促す薬を服用し、卵子を取り出して体外で精子と受精させ、できた受精卵を女性の子宮に戻す方法がある。これを体外受精（IVF）という。なかなか妊娠しない女性の中には、多嚢胞性卵巣症候群（卵巣で成熟卵子をうまく作れない状態）の人がいる。このような女性が卵子の成熟を促す薬を服用すると、卵子が過剰に作られることがある（卵巣過剰刺激症候群と呼ばれる）。これは卵巣が腫れて痛みを伴い、重篤な病気や（まれには）死に至ることもある。多...

喘息児やその介護者または両方に、在宅で喘息教育を提供するのはどれだけ役に立つか？ 主なメッセージ 在宅教育を行うと、他所でなされる教育と比べて生活の質 (QOL)が向上するほか、その介入の度合いが低い場合と比べて入院回数が減るという限定的なエビデンスがある。 救急外来の受診や副腎皮質ステロイド薬（気道内の炎症（腫れ）を抑える喘息治療薬）を使った治療が必要となるほどの喘息の悪化、喘息の症状または肺の機能状態の変化に関して、在宅で行う教育が他所で行う教育より優れているか劣っているかを示す十分なエビデンスはない。 - 実際に喘息教育のどの要素が喘息の知識の向上と結果（評価項目）の改善につながるかを調べるには、周到にデザインされた試験が必要である。 喘息とは？ 喘息とは慢性の（長期の）肺疾患である。喘息をもつ人は肺の気道内で炎症（腫れ）が起きる。症状は喘鳴、息苦しさ、胸の圧迫感、咳である。 喘息教育とは？ 喘息教育は、患者と医療従事者の協力関係を利用して、患児と介護者に喘息をどのように管理するか教えることを目的とする。喘息教育の内容としては、喘息に関する情報、吸入器の効果的な使い方を含む喘息管理の訓練、管理の方策、薬の正しい用法の指導などがある。ピークフローメーター（手に持って、全力でどれだけ速く息を吐けるか測定する器具）などを用いた喘息のモニタリングと医療従事者による定期検査も喘息教育...

Honouring Cochrane's Volunteer Translators: Bridging Language Gaps in 2024

Cochrane proudly celebrates the incredible efforts of our volunteer translators in 2024. Their dedication has been instrumental in breaking language barriers and making high-quality health information accessible to communities worldwide.

This year, more than 730 volunteers actively contributed to our translation programme, with 48.6% coming from lower- or middle-income countries. Some language teams work with a larger number of volunteers than others, showcasing the diverse nature of our global multi-language programme.

In 2024 alone, our translation teams have published over 6,056 new or updated plain language summaries—and, for some languages, abstracts as well—bringing the total number of review summary translations to an impressive 54,272. This extraordinary collective effort ensures that Cochrane's trusted, evidence-based health information reaches those who need it most, regardless of the language they speak.

Beyond the numbers, the dedication of our volunteers is truly inspiring. Many of them balance their translation work with professional and personal commitments, yet they remain steadfast in their mission to improve global health literacy. 

Inès Belalem, volunteer in the French translation team, shared:

Pagakrong Lumbiganon from the Thai translation team reflected:

We extend our deepest gratitude to everyone involved in Cochrane’s translation projects for their unwavering commitment. Your contributions are invaluable, and together, we are making a meaningful impact on global health.

Thank you for being an essential part of Cochrane’s mission to provide accessible, high-quality health information to all.

About Cochrane's Multi-Language Programme

Cochrane translates evidence-based health information into multiple languages to improve accessibility and reduce linguistic barriers to global evidence-informed health decisions. We regularly translate content into languages including Croatian, Dutch, French, German, Hindi, Hungarian, Indonesian, Japanese, Korean, Malay, Persian, Polish, Portuguese, Romanian, Russian, Spanish, Simplified Chinese, Thai, and Traditional Chinese.

Only around 6% of the world’s population are native English speakers, and 75% of people do not speak English at all. Many individuals lack access to high-quality health information simply because it is not available in a language they understand. By translating Cochrane evidence, we aim to bridge this gap and ensure that everyone, regardless of language, can make informed health decisions.

•  If you are interested in joining our community of volunteer translators and contributing to this vital work, please click here for more information on how to get involved.

 

Monday, February 3, 2025

Thursday, January 30, 2025

子どもの肥満を管理するのに、精密栄養学に基づく介入をするとどんな効果があるのか？ 要点 - 精密栄養学（個人の生物学的特徴や環境に基づいて、その人に合った食事や食品を提供すること）が、肥満の子どもの体重や体格指数（BMI）で測定される体重の変化に効果があるかどうかは不明である。 - 子どもの肥満を管理するのに、精密栄養学に基づく介入がどんな効果があるのかを理解するためには、大規模なものを含む研究がさらに必要である。 過体重と肥満症とは何か？ 体格指数（BMI）は、体重（キログラム）を身長（メートル）の二乗で割って算出する。BMIは、脂肪をたくわえ過ぎた状態である「過体重」と、健康を害するほど脂肪をたくわえ過ぎていることが特徴の慢性疾患である「肥満症」を定義するために使用されることがある。 過体重や肥満症はどのように管理されるのか？ 肥満症は、食事や生活習慣の改善、手術、薬物療法によって管理できる。一方で、2022年現在、5歳未満の子ども約3,700万人が肥満症になっている。また、青年の肥満症の割合は、1990年の4倍にまで増えている。これは、個別化または精密栄養学に基づく介入など、治療に対する代替的または補完的方法が必要であることを示している。 何を調べようとしたか？ 最近、「精密栄養学」（個人の行動、生理学的特徴、ライフスタイル、食事が、介入にどのように利用できるかを研究する学...

全般性不安障害の抗うつ薬 主なメッセージ - 抗うつ薬はプラセボ（見せかけの錠剤）よりも治療反応を改善する効果が高く、プラセボと同程度の受容性がある。プラセボ群に比べ抗うつ薬群では効果不足による脱落者が少なく、プラセボ群に比べ抗うつ薬群では好ましくない作用による脱落者が多かった。 - 今後の研究では、方法と結果の報告がより透明化されるかもしれない。今後のレビューでは、併存する病状を持つ人々も含めるかもしれない。 全般性不安障害とは何か？ 全般性不安障害は、日常的な出来事に対する過剰な不安と継続的な心配を特徴とする精神疾患である。全般性不安障害はよく見られるもので、一般に女性は男性の2倍の頻度で罹患する。 全般性不安障害はどのように治療するのか？ 治療法には、さまざまな心理学的アプローチ（心や人の行動に働きかける）や薬がある。薬の中では、抗うつ薬（うつ病の治療に用いられる）、特に選択的セロトニン再取り込み阻害薬とセロトニン・ノルアドレナリン再取り込み阻害薬と呼ばれる2種類の抗うつ薬が全般性不安障害の治療によく用いられ、多くの研究でプラセボによる偽治療に対する有用性が示されている。 このレビューに関心を持つ人は誰か？ 全般性不安障害がある人、一般開業医、メンタルヘルス専門家。 知りたかったこと このレビューでは、このトピックに関して利用可能なすべてのエビデンスの最新の要約を提供するこ...